Comprehensive molecular phenotyping of ARID1A -deficient gastric cancer reveals pervasive epigenomic reprogramming and therapeutic opportunities. Chang Xu , Kie Kyon Huang , Jia Hao Law , Joy Shijia Chua , Taotao Sheng , Natasha M Flores , Melissa Pool Pizzi , Atsushi Okabe , Angie Lay Keng Tan , Feng Zhu , Vikrant Kumar , Xiaoyin Lu , Ana Morales Benitez , Benedict Shi Xiang Lian , Haoran Ma , Shamaine Wei Ting Ho , Kalpana Ramnarayanan , Chukwuemeka George Anene-Nzelu , Milad Razavi-Mohseni , Siti Aishah Binte Abdul Ghani , Su Ting Tay , Xuewen Ong , Ming Hui Lee , Yu Amanda Guo , Hassan Ashktorab , Duane Smoot , Shang Li , Anders Jacobsen Skanderup , Michael A Beer , Roger Sik Yin Foo , Joel Shi Hao Wong , Kaushal Sanghvi , Wei Peng Yong , Raghav Sundar , Atsushi Kaneda , Shyam Prabhakar , Pawel Karol Mazur , Jaffer A Ajani , Khay Guan Yeoh , Jimmy Bok-Yan So , Patrick Tan Gut（2023）
摘要
Our results suggest a therapeutic strategy for -mutated GCs targeting both tumour-intrinsic (BRD4-assocatiated promoter activation) and extrinsic (NFKB immunomodulation) cancer phenotypes.
更多 查看译文
AI 理解论文
溯源树
样例
